$heff's $tation of $tocks & $olid DD

[$heff]

#Biotech Clinical Data in Q3/Q4 14
$ACST end Q3 ph2
$AVNR P3-late Q3
$CPRX Firdapse Ph 3-Aug/Sept
$ICPT P2 Flint-Aug
$Xoma (XOMA) Clinical Ph 3 EYEGUARD-B data for Gevokizumab in Behcet's uveitis (Aug/Sept)
$OXGN-P2 9/26 GOG
$SNSS-late Q3/early Q4 Valor Data due.
$THLD P3 interim (Mid-Sept)
$TRGT P2-Q4
$TNXP TNX-102 Q4

-Aug 10-13 Epizyme (EPZM) Clinical Preliminary data from Ph 1 trial of EPZ-6438 at ASH Meeting on Lymphoma Biology

Aug Intercept (ICPT) Clinical Full data incl. 24-week follow-up from Ph 2 FLINT trial of OCA in NASH

end of Q3:14 Anacor (ANAC) Commercial US launch of Kerydin for onychomycosis

Aug/Sep Xoma (XOMA) Clinical Ph 3 EYEGUARD-B data for Gevokizumab in Behcet's uveitis

Sept 11 Infinity (INFI) and Regulatory PDUFA date for Idelalisib (competitor to IPI-145 and Imbruvica) from

Gilead for non-Hodgkin's lymphoma Pharmacyclics (PCYC)

Sept 12 NPS (NPSP) Regulatory FDA Advisory Committee to discuss BLA for Natpara (recombinant parathyroid hormone)

Sept 10-13 Receptos (RCPT) Clinical Potential presentation of full Ph 2 RADIANCE data at ACTRIMS-ECTRIMS meeting

Sept 18 Medivation (MDVN) Regulatory PDUFA date for sNDA for Xtandi in pre-chemo metastatic CRPC

Sept26-30 Endocyte (ECYT) Clinical Updated data from Ph 2b TARGET study of vintafolide in folate-receptor positive NSCLC presented at ESMO

H2:14 Fate (FATE) Clinical Interim update from Ph 2 PUMA study of ProHema in patients with hematologic malignancies

H2:14 Novavax (NVAX) Clinical Top-line data from Ph 1/2 trial of H7N9 avian flu VLP vaccine with Matrix-M adjuvant

H2:14 NPS (NPSP) Commercial European launch of Revestive (Gattex)

H2:14 Omeros (OMER) Comm/Reg US Launch and potential EU approval for Omidria

H2:14 Pharmacyclics (PCYC) Clinical Data from Ph 2 trials of Imbruvica in MM and CLL/SLL patients with 17p deletion (RESONATE-17)

H2:14 Sunesis (SNSS) Regulatory Top-line data from Ph 3 VALOR trial of vosaroxin

H2:14 Xencor (XNCR) Clinical Top-line data from Ph 2 trials of MOR208 in ALL and XmAb5871 in rheumatoid arthritis

H2:14 Xoma (XOMA) Commercial Potential partnership for XMet program in diabetes

Oct 7 Pharmacyclics (PCYC) Regulatory PDUFA date for Imbruvica for r/r CLL/SLL (already approved under accelerated pathway)

Oct 24 NPS (NPSP) Regulatory PDUFA date for Natpara for hypoparathyroidism

Nov 7-11 Intercept (ICPT) Clinical Detailed FLINT Ph 2b OCA/NASH results at AASLD in Boston

Nov 11-16 La Jolla (LJPC) Clinical Detailed results of Ph 2a trial of GCS-100 in CKD at American Society of Nephrology meeting

Nov 13-16 Celldex (CLDX) Clinical updated data from Ph 2 ReACT trial of rindopepimut in recurrent glioblastoma presented at SNO meeting